Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169600 | 1.00 | NFE2L2 (0.46) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL4772823 | 0.88 | NFE2L2 (0.43) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL4772837 | 0.88 | NFE2L2 (0.43) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL3899639 | 0.82 | NFE2L2 (0.50) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL2451125 | 0.82 | NFE2L2 (0.50) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL17862090 | 0.81 | NFE2L2 (0.59) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL21411331 | 0.78 | NFE2L2 (0.45) | NFE2L2PTGS1FBP1GRIK1GRIK2 | |
| SCHEMBL21411330 | 0.78 | NFE2L2 (0.45) | NFE2L2PTGS1FBP1GRIK1GRIK2 | |
| SCHEMBL8975003 | 0.78 | NFE2L2 (0.46) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL7097687 | 0.78 | HSD11B1 (0.47) | NFE2L2HSD11B1APPPTGS1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346835-A1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS, THEIR USE AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20110177950-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing the Same | BASF SE (DE) | 2011-07-21 | — | — | US | disclosed |
| WO-2010031843-A1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS, THEIR USE AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177950-A1 | Imidazole and Triazole Compounds, Their Use and Agents Containing the Same | COX4I1, CYP2C19, CYP3A43 | NFE2L2 1647/4885HSD11B1 1002/4885APP 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.